ABSTRACT: Compound W, a 3,3=-diiodothyronine sulfate (T 2 S) cross-reactive material in maternal serum, was found to be useful as a marker for fetal hypothyroidism. In the present report, we explored its biochemical properties and studied its concentrations in cord and in maternal serum obtained from various gestational periods and at term from different continents. Mean W concentrations, expressed as nmol/L T 2 S-equivalent, in maternal serum during gestation showed a moderate increase at 20 -26 wk (1.57 nmol/L) and an accelerated increase to 34 -40 wk (3.59 nmol/L). The mean serum level was relatively low in nonpregnant women (0.17 nmol/L). Compound W levels in cord and maternal serum at term were not significantly different among samples obtained from Taiwan compared with samples from the United States. The mean cord serum "corrected" (by hot acid digestion) concentrations of W were significantly higher than maternal serum concentrations at birth and were also higher in venous than in paired arterial samples, suggesting that the placenta may play a role in its production. We compared a total of 45 iodothyronine analogs by antibody, gel filtration, and HPLC chromatographic studies and found only one compound, N,N-dimethyl- E mploying a sensitive RIA for T 2 S, we found high concentrations in fetal and pregnant serum in humans (1). We further identified that this T 2 S-cross-reactive material is not authentic T 2 S and does not co-chromatograph with synthetic T 2 S on HPLC. Thus, the name Compound W was coined to represent this material in fetal and maternal serum (1). Levels increased with the progression of pregnancy and rapidly peaked before parturition. At delivery, a 20-fold increase in "T 2 S" was found compared with nonpregnant women and returned to baseline within 7-10 d. Serial measurements of serum W in pregnant women have been found to be useful as a noninvasive technique for the diagnosis of fetal hypothyroidism (2,3).
Identification and characterization of Compound W. T 2 S immunoreactivity was studied in maternal or cord serum extracts by acid hydrolysis, HPLC, and RIA. Five to 10 mL cord or maternal serum were extracted with 2 vol 95% ethanol and subsequently lyophilized. The dried extracts were dissolved in H 2 O and purified with an LH-20 column, as previously described (1, 6) . Radioactive or nonradioactive T 2 S-supplemented serum extracts from nonpregnant women were used to identify the T 2 S peak on HPLC. To study hot-acid stability, the serum samples were digested in 0.5 N HCl at 80°C for 1 h to hydrolyze the authentic T 2 S and then assayed as described by Mol and Visser (1, 5) .
Synthesis of N,N-dimethyl-T 2 S (DMT 2 S).
A synthesized novel thyroid hormone derivative has been found to co-chromatograph with W on HPLC and cross-react to T 2 S antibody. Equimolar T 2 S and iodomethane were allowed to react in dimethylformamide at room temperature for 30 s and dried in N 2 . Dried samples were dissolved in 0.02 N NaOH and purified by HPLC. The purified product was analyzed by T 2 S RIA and high-resolution mass spectrometry (MS) (9, 10) . RIA analysis revealed a T 2 S-reactive peak, the elution time of which coincided with W peak on HPLC. The purified compound was found nonreactive to ninhydrin reagent, suggesting the loss of the amino group in the alanine side-chain. LC/MS/MS analysis, using a custom-built capillary RPC18 column (150 ϫ 5 cm) HPLC system coupled to a trap mass spectrum, demonstrated a spectrum consistent with N,Ndimethyl-T 2 S (DMT 2 S) (Beckman Research Institute, City of Hope, Los Angeles, CA).
Sources of samples and materials. Serum samples were obtained from 195 pregnant women (17-40 y of age) with estimated gestational ages ranging from 3 to 40 wk and 33 venous cord blood at delivery from Taiwan. All blood-sampling protocols were approved by the Tri-Service General Hospital clinical research committee, and informed consent was obtained from all patients. In addition, 473 paired and 258 nonpaired maternal-cord, male euthyroid, and hyperthyroid patients' banked serum samples from Thailand, Colombia, Taiwan, and the United States were obtained.
3-Iodothyronine (3-T 1 ), 3=-iodothyronine (3=-T 1 ), 3,3=-diiodothyronine (3,3=-T 2 ), 3=,5=-diiodothyronine (3=,5=-T 2 ), 3,3=,5-triiodothyronine (3,3=,5-T 3 ), 3,3=,5=-triiodothyronine (3,3=,5=-T 3 ), thyroxine (T 4 ), 3,5-diiodothyronamine (3,5-diam), 3,3=,5-triiodothyronamine (3,3=,5-triam), and 3,3=,5,5=-tetraiodothyronamine (tetram) were purchased from Henning-Berlin Co. (Berlin, Germany). Ninhydrin reagent, 3,3=,5-triiodothyroacetic acid (3,3=,5-triac), 3,3=,5,5=-tetraiodothyroacetic acid (tetrac), 3,5-diiodothyropropionic acid (3,5-diprop) , and 3,3=,5-triiodothyropropionic acid (3,3=,5-triprop) were purchased from Sigma Chemical Co. (St. Louis, MO). Sulfoconjugated analogs, including T 2 sulfamates, were synthesized by the methods of Mol and Visser (5) . Glucuronidated analogs were produced by the methods of Hays and Hsu (11). 3,3=-Diiodothyroacetic acid (3,3=-diac) and 3,3=-diiodothyropropionic acid (3,3=-diprop) were synthesized by the iodination of 3-monoiodothyroacetic acid (3-monac) and 3-monoiodothyropropionic acid (3-monoprop). 3-Monac, 3-monoprop, and O-methyl-T 2 were obtained through the kind assistance of Dr. Hans Cohmann.
[ 125 I]3,3=-T 2 was prepared by radioiodination using the method described previously (12 Statistical analysis. Unpaired t test was used to assess between-group differences. ANOVA was used to test multigroup comparisons. If significant differences were present, Dunnett's multicomparison test was used to compare the control or baseline mean and the mean values of other groups (13) . Significance was defined as p Ͻ 0.05. Results are reported as the mean Ϯ 1 SD (or 1 SE in Fig. 3 ). In addition, simple linear regression analysis of the serum Compound W concentrations was used to test the correlation between at-term pregnant women samples and the paired cord samples (14) .
RESULTS
Normal values of serum T 2 S-equivalent levels in pregnant women. A total of 195 serum samples from pregnant women from Taiwan at gestational ages ranging from 3 to 40 wk were examined. Serum mean concentrations of T 2 S-cross-reactive material (expressed as T 2 S equivalent) were elevated at 3-7 wk (n ϭ 37, 0.98 nmol/L) compared with nonpregnant women (n ϭ 17, 0.17 nmol/L; p Ͻ 0.01). Mean levels were found not to increase significantly at 8 -13 wk (n ϭ 32, 0.83 nmol/L; p ϭ 0.17 versus 3-7 wk) or at 14 -19 wk (n ϭ 37, 1.17 nmol/L; p ϭ 0.12 versus 3-7 wk). Moderate increases were noted at 20 -26 wk (n ϭ 17, 1.57 nmol/L; p Ͻ 0.01 versus 3-7 wk) and at 27-33 wk (n ϭ 50, 2.38 nmol/L; p Ͻ 0.01 versus 3-7 wk). An accelerated increase was noted at 34 -40 wk (n ϭ 22, 3.59 nmol/L; p Ͻ 0.01 versus 3-7 wk) ( Table 1 , Fig. 1 ). The 20 -40 wk increase correlates with the timing and progressive increase in fetal thyroid hormone secretion in utero. Correlation between fetal and maternal serum T 2 Sequivalent and Compound W Concentrations. Figure 2 shows the concentrations of T 2 S equivalent in 436 pairs of maternal serum and cord blood samples. The correlation coefficient of the linear regression was 0.686 (p Ͻ 0.01). In Figure 3 , the mean (Ϯ1 SE) of the maternal serum concentrations of T 2 S-reactive material (3.81 Ϯ 0.07 nmol/L or 1.36 nmol/L for 1 SD) was significantly lower than that of the paired cord serum concentrations (4.91 Ϯ 0.06 nmol/L or 1.31 nmol/L for 1 SD; p Ͻ 0.01 versus maternal levels). In our previous study, the authentic T 2 S was hydrolyzed by hot-acid digestion (1) . Using this procedure, the recovery of T 2 S-crossreactive material (mean Ϯ 1 SE) was 77.1 Ϯ 2.2% in cord serum (n ϭ 6) and 87.4 Ϯ 3.2% in maternal serum (n ϭ 12; Fig. 3 ). The maternal and paired cord serum concentrations of T 2 S-reactive material in Figure 2 were adjusted by these percentages to obtain the hot-acid-resistant T 2 S-equivalent activity, or the "corrected" Compound W level. The "corrected" W mean level (Ϯ1 SE) was still significantly higher in cord serum (3.79 Ϯ 0.05 nmol/L) than in maternal serum (3.33 Ϯ 0.06 nmol/L; p Ͻ 0.01).
T 2 S-equivalent values in cord and maternal serum at term from different geographic regions. Cord and at-term maternal serum samples from Asia (Taiwan) and the United States from normal pregnancy were studied. The serum T 2 S-equivalent concentrations in cord and at-term maternal samples were (Table 2 ). However, cord and maternal serum samples from Thailand and Colombia were found to have slightly but significantly higher values (Table 2) . Possible origin of Compound W. Figure 4 shows the serum concentrations of sulfated iodothyronines from cord arterial and venous samples (n ϭ 8 -9). There were no significant differences between the mean T 3 S, T 4 S, or rT 3 S concentrations of arterial and venous serum samples. However, the venous T 2 S-equivalent concentration was higher than arterial in seven of the paired samples and lower in two. The mean "corrected" W concentration in nine pairs of cord serum was found to be significantly higher in venous samples (2.67 Ϯ 0.94 nmol/L) than in arterial samples (2.27 Ϯ 0.91 nmol/L; p Ͻ 0.04).
Compound W: characterization and comparison with other analogs. A total of 45 known synthetic thyroid hormone analogs, synthesized, obtained commercially, or obtained as gifts from other laboratories, were subjected to HPLC and T 2 S RIA, and their characteristics were compared with those of Compound W (Table 3) .
The cross-reactivities of various other thyroid hormone analogs were studied, and only T 4 S, TriacS, rT 3 S, and T 3 S cross-reacted significantly (3.2%, 1.7%, 1.4%, and 0.02%, respectively) (1). Other nonsulfated iodothyronines and sulfated steroids cross-reacted Ͻ0.0001% (1) . Only N,Ndimethyl-T 2 S was found to be in close similarity to Compound W in its retention time on HPLC and reaction to T 2 S-specific antibody.
DISCUSSION
In developing mammals (including humans), a deficiency or excess of thyroid hormone (TH) in the developing brain during the fetal and neonatal periods can lead to morphologic and functional abnormalities (15) (16) (17) (18) . The most severe form of TH deficiency in human fetus and neonate is the syndrome of cretinism. A milder form of fetal TH deficiency is observed in children of women with subclinical hypothyroidism during pregnancy as assessed by IQ and other neuropsychological tests (19 -21) .
In sheep, a precocial species similar to humans, it has been shown that a significant amount of T 3 formed in the fetal circulation is converted to T 2 S and transferred to the maternal compartment for deiodination/excretion (22, 23) . This process may serve to maintain low circulating T 3 levels in the fetus. Since T 2 S appears to be quantitatively derived from circulating T 3 in the fetus, a significant increase or decrease in T 2 S in the maternal circulation would suggest hyper-or hypothyroidism in the fetus (22) . Based on previous studies in sheep, our working hypothesis is that placental tissue, with its iodothyronine sulfotransferase(s) and type 3 deiodinase (D3), may be the site of sulfation that facilitates the unidirectional transfer of T 2 S from the fetal to the maternal circulation in pregnant ewes (in humans T 2 S is proposed to be further metabolized to Compound W; Fig. 5 ). The postulated immediate precursor for W is 3,3=-T 2 S. T 2 S could be derived from T 3 S by the activities of type 1 deiodinase (D1), which generally is low in fetuses. A more likely route would be from the inner-ring deiodination of T 4 to rT 3 by D3, and then to T 2 which is an excellent substrate for sulfotransferases hSULT1A1 and hSULT1E1 (3). T 3 is a poor substrate to both sulfotransferases and could be readily converted to T 2 by D3. The higher level of W in venous cord blood than that in arterial samples suggests that the placenta may play a role in its production and preferential transfer to the maternal compartment (Fig. 4, Fig.  5 ). By removing fetal circulating iodothyronines, e.g. T 3 , it may critically regulate the homeostasis of thyroid hormones in the fetus, especially in the later stage of development when D1 begins to mature in fetal tissues (8, 24, 25) .
Prior studies identified that a T 2 S-cross-reactive material, Compound W, is not authentic T 2 S, and does not cochromatograph with synthetic T 2 S on HPLC in fetal and maternal serum (1) . Maternal levels increased with the progression of pregnancy and rapidly peaked before parturition. Serial measurements of serum W in pregnant women have been found to be useful as a noninvasive technique for the diagnosis of fetal hypothyroidism in pregnancies associated with fetal goiter (2, 3) . In the present report, we established the "normal" levels, expressed as T 2 S-equivalent, in different gestation periods (Table 1) and also showed the majority of the T 2 S-cross-reactive material is W in maternal serum at term (Fig. 3) . The increased levels of serum W in early pregnancy (Fig. 1) , before the beginning of fetal thyroid hormone production, are in agreement with the increase in maternal T 4 needs and the apparent maternal to fetal transfer of T 4 (Fig. 5) . The presence of TH in the fetus (26, 27) and the access to the placenta appear to be critical for the production of Compound W. We also showed that there are similar cord and maternal levels at term in samples from the United States compared with those from Taiwan, where all the "normal" samples in Table 1 were obtained. Samples from other regions, including Thailand and Colombia, were found to have a slight but significant increase in cord and maternal serum at term (Table  2) . Since the exact iodine intakes in these regions are unknown, the cause(s) of this difference is not clear and deserves further study.
Authentic T 2 S is hydrolyzed by hot-acid digestion and constitutes a minor fraction in total T 2 S-cross-reactivity in serum from mother at term or from cord (Fig. 3) . The adjustment of Compound W values for the hot-acid-resistant T 2 Sequivalent activity revealed that fetal "corrected" Compound W levels are significantly higher than those in maternal sera (Fig. 3) . On the other hand, significantly more authentic T 2 S in cord samples than in maternal samples is consistent with higher circulating sulfated iodothyronines in developing mammals, likely a result of lower D1 activity compared with adults (3).
The higher level of W in venous cord blood than that in arterial samples is consistent with our postulation that the placenta may play an essential role in its production and preferential transfer to the maternal compartment (Fig. 4) . Interestingly, other iodothyronine sulfates, including T 3 S, T 4 S, and rT 3 S, are found at essentially the same levels in (28) have demonstrated that serum T 4 S levels exhibit a postnatal transient increase in preterm infants. It is not known whether there is a similar increase in T 2 S. It would be interesting to study the serum content of preterm infants; an increase in T 2 S without a significant corresponding increase in Compound W, i.e., a significant decrease in percentage of W compared with cord ( Fig. 3) , would suggest nonfetal origin of Compound W. Serum levels of T 2 S-immuno cross-reactive material have been recently measured by Chopra (29) . In this UCLA study, compared with normal subjects (mean T 2 S-equivalent value, 0.86 nmol/L) there is a significant rise in T 2 S-immuno crossreactive material in pregnant women with different gestational ages (2.7 nmol/L) and in newborn cord serum samples (18 nmol/L). It is not clear why the normal serum level was 5-fold higher than that in our nonpregnant women (0.17 nmol/L). Chopra's data are somewhat difficult to interpret, since HPLC and hot-acid digestion were not used to separate T 2 S from Compound W in the study (29) . Nevertheless, Chopra's data independently demonstrate that there is an increase in T 2 Scross-reactive material in pregnant and fetal serum. In the Chinese mainland, Chen et al. (33) found a mean serum concentration of 0.23 nmol/L in nonpregnant women and a progressive rise with gestational age to a mean of 2.79 nmol/L in pregnant women in the third trimester, similar to our values in normal pregnancy ( Table 1) .
The chemical structure of Compound W remains to be elucidated. In the present report we evaluated 45 thyroid hormone analogs and found that only one, N,N-dimethyl-T 2 S, is biochemically and immunologically similar to Compound W. However, this novel compound has not yet been identified in human biologic fluids, nor has its presence been determined 4, 2005) ; application of W measurements in pregnancies associated with fetal goiter, in association with serial ultrasonographic measurement, may allow reduced reliance on cordocentesis for fetal therapy management in these cases (34, 37) .
